Claritas Pharmaceuticals, Inc. (CLAZF)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: May 19, 2025
Claritas Pharmaceuticals Company Description
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs.
The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021.
Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.
Claritas Pharmaceuticals, Inc.
| Country | Canada |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Robert Farrell |
Contact Details
Address: 4040 Civic Center Drive San Rafael, British Columbia 94903 United States |
Stock Details
| Ticker Symbol | CLAZF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CA1806342061 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert Farrell J.D. | Chairman, Chief Executive Officer and President |
| Victoria Diana Rudman | Interim Chief Financial Officer, Treasurer and Secretary |
| Seth Yakatan | Co-Founder |
| Dr. Stuart L. Silverman FACP, FACR, M.D. | Chair of Scientific Advisory Board and Vice President of Medical Affairs |
| Dr. Sari Prutchi-Sagiv Ph.D. | Chief Scientific Officer |
| Dr. Moshe Yeshurun M.D. | Chief Medical Officer |
| Dr. Amos Rosenthal Ph.D. | Head of Chemistry |